Developed by Ascentage Pharma, lisaftoclax is a novel orally available Bcl-2 inhibitor with clinical benefits for an array of hematologic malignancies and solid tumors. At this year's ASH Annual ...

The phosphatidylinositol 3-kinase (PI3K)-AKT signaling pathway is one of the most critical ... has identified focal adhesions ...

Verastem Oncology has concluded the rolling submission of a new drug application (NDA) to the US Food and Drug Administration ...

Verastem initiated the rolling NDA submission in May. Credit: Jo Panuwat D via Shutterstock. Verastem Oncology has concluded the rolling submission of a new drug application (NDA) to the US Food and ...

LONDON & NEW YORK--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating access to evidence-based innovation in mental health ...

But against this backdrop, change is afloat. Here in northeastern Alberta, Pathways Alliance seeks a proving ground. Pathways Alliance, a group of the six largest oilsands companies, is planning to ...

The alternative complement pathway plays a key role in the pathogenesis of IgA nephropathy. Iptacopan specifically binds to factor B and inhibits the alternative pathway. In this phase 3 ...

Zhejiang Key Laboratory of Data-Driven High-Safety Energy Materials and Applications Ningbo Key Laboratory of Special Energy Materials and Chemistry, Ningbo Institute of Materials Technology and ...

With funding from charity Kidney Research UK, Dr Carl May from Bristol Medical School and his team have identified a new treatment pathway for ... kidney failure. Focal segmental ...